Devonian Health Group Inc. reports developments as a clinical-stage biopharmaceutical company focused on therapies for fibro-inflammatory diseases. Company news centers on Thykamine™, including preclinical data in MASH and pulmonary fibrosis models, anti-inflammatory and anti-fibrotic research, intellectual-property filings, manufacturing controls and its radiodermatitis prevention program.
Recurring updates also cover Devonian's cosmeceutical activities, its Quebec extraction facility and Altius Healthcare Group LP, a commercialization subsidiary that sells licensed prescription pharmaceutical products in Canada. Corporate news includes financial results, board and management changes, shareholder meeting outcomes, stock-option grants and capital-structure actions such as its common-share consolidation.
Devonian Health Group (DVHGF) continues preparations for its proposed NYSE American listing and initial public offering in the United States. The company is working with ThinkEquity to prepare the offering and listing of common shares and warrants under the proposed symbols DHGR and DHGR WS, respectively.
The revised anticipated trading commencement date and expected offering closing date remain undetermined. Completion depends on market conditions and required regulatory approvals, including those of NYSE American and the TSX Venture Exchange. Devonian remains listed on the TSXV and plans to announce revised dates in a future update.
Devonian Health Group (DHGR, DVHGF) expects its common shares and warrants from an underwritten public offering to begin trading on the NYSE American as early as September 16, 2026, under the symbols “DHGR” and “DHGR WS”.
The listing and start of trading are subject to market conditions, final NYSE American authorization of the company’s listing application, and continued compliance with exchange rules. Devonian will remain listed on the TSX Venture Exchange, where it has reserved the symbol “DHGR” and plans to request a change of its current symbol from “GSD” to “DHGR” at a later date.
Devonian Health Group (OTCQB: DVHGF, TSXV: GSD) announced independent validation and integration of key analytical and biological quality-control methods into the extraction and manufacturing of Thykamine™, its lead botanical drug candidate for fibro-inflammatory diseases.
Validated HPLC-MS chemical fingerprinting by Chromak Research and a U-937 cell-based biological potency assay measuring MIP-1β by Pacific BioLabs are now embedded in Devonian's QA/QP program. NMR spectroscopy is used as an orthogonal tool, with analyses to date showing >98% batch-to-batch chemical reproducibility. Ongoing external testing is expected to verify chemical consistency and biological activity across future Thykamine™ batches, aligning with FDA botanical drug development guidance for combined chemical and biological control strategies.
Devonian Health Group (OTCQB: DVHGF) announced that, in connection with an underwritten public offering, it anticipates listing its common shares and warrants on the NYSE American, with trading expected as early as August 21, 2026 under symbols “DHGR” and “DHGR WS”, subject to market conditions and final NYSE American authorization. The company will remain listed on the TSX Venture Exchange and has reserved symbol “DHGR” there, intending to change its TSXV trading symbol from “GSD” to “DHGR” at a later date.
Devonian Health Group (TSXV:GSD, OTCQB:DVHGF) announced a proposed underwritten public offering of common shares (and/or pre-funded warrants) and warrants, together with an expected listing of its common shares and warrants on the NYSE American under the symbols DHGR and DHGRW, respectively. The listing remains subject to final authorization of the company's application and ongoing compliance with exchange rules, and the Offering is subject to market conditions and regulatory approval, with size and pricing yet to be determined.
According to Devonian, its shares are expected to continue trading on the OTCQB until pricing of the Offering, after which OTCQB trading will terminate once the NYSE American listing is effective. The company has also reserved the symbol DHGR on the TSX Venture Exchange and intends to change its current symbol from GSD to DHGR at a later date. ThinkEquity is acting as sole book-running manager, and a registration statement has been filed with the SEC but is not yet effective; no securities will be offered or sold to investors resident in Québec or elsewhere in Canada in connection with this Offering.
Devonian Health Group (OTCQB: DVHGF) received Health Canada authorization to initiate a seamless adaptive Phase II/III clinical trial of PUR 0110 (Thykamine™) cream in pediatric patients with mild-to-moderate atopic dermatitis, covering the full intended age range from 3 months to 17 years.
The 12-week, randomized, double-blind, placebo-controlled study will enroll approximately 306 patients, testing 0.05% and 0.1% Thykamine™ cream versus placebo. The primary endpoint is Week 12 treatment success based on vIGA-AD (Clear/Almost Clear with ≥2-grade improvement). An independent safety committee will oversee adverse events, age-cohort progression, and a Phase II futility analysis to determine seamless transition to Phase III.
According to Devonian, this pediatric program builds on a prior adult Phase II trial in atopic dermatitis where Thykamine™ showed statistically significant efficacy and an excellent safety profile, and is supported by a global patent portfolio for the Thykamine™ and SUPREX™ platforms.
Devonian Health Group (OTCQB: DVHGF, TSXV: GSD) reported Q3 2026 and nine‑month results. Q3 net loss was $1.9M or $0.70/share, versus $4.8M or $1.94/share a year earlier. Nine‑month net loss was $5.7M or $2.07/share, compared with $5.6M or $2.28/share.
Cash totaled $0.7M on April 30, 2026, down from $7M on July 31, 2025; the company remains debt‑free. Devonian raised $2M via two private placements plus $0.2M from warrant exercises and is prioritizing development of Thykamine in radiodermatitis, pediatric atopic dermatitis, and exploratory work in MASH and fibrotic diseases.
Devonian Health Group (OTCQB: DVHGF) reported the results of its annual general and special meeting held March 27, 2026.
Shareholders elected eight directors, appointed MNP LLP as auditor for the fiscal year ending July 31, 2026, and approved an amendment to increase the stock option pool to 20% of issued shares (post‑consolidation), subject to TSXV final approval.
Devonian Health Group (OTCQB: DVHGF) reported a Q2 2026 net loss of $2.2M ($0.81/share) and a six-month loss of $3.8M ($1.37/share). Cash fell to $1.3M at January 31, 2026 from $7.0M on July 31, 2025. The company effected a 60-for-1 reverse share split on January 22, 2026 and remains debt-free.
Devonian is refocusing on its Thykamine™ biopharmaceutical program, prioritizing a pivotal radiodermatitis prevention study, advancing preclinical MASH and fibrosis work, and evaluating strategic options for its Altius distribution business.
Devonian (OTCQB: DVHGF) reported Feb 19, 2026 preclinical human liver-on-a-chip results showing dose-dependent anti-fibrotic and anti-inflammatory activity for Thykamine™. In a 14-day PhysioMimix® MASH model, Thykamine reduced fibrosis biomarkers, Type I collagen deposition and lowered IL-6/IL-8, with strongest effects at 0.1–0.2 mg/mL.
LDH remained low (no drug-induced liver injury signal). Company plans additional preclinical studies to further characterize disease-modifying potential in MASH and other fibrotic diseases.